Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 108 clinical trials
  • 0 views
  • 15 Sep, 2022
  • 149 locations
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma (DREAMM 9)

This study will evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of belantamab mafodotin in combination with Velcade (bortezomib), Revlimid (lenalidomide

neutrophil count
velcade
chemotherapy regimen
bortezomib
measurable disease
  • 14 views
  • 09 Aug, 2022
  • 31 locations
A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis (AQUARIUS)

The purpose of this study is to characterize cardiac safety of Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (D-VCd) treatment regimens (Arm A: immediate daratumumab + VCd

amyloid deposition
dexamethasone
daratumumab
cyclophosphamide
  • 5 views
  • 20 Sep, 2022
  • 12 locations
Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP)

>Arm 2: Selinexor + dexamethasone + bortezomib (SVd); enrollment complete Arm 3: Selinexor + dexamethasone + lenalidomide (SRd) in RRMM; enrollment complete Arm 4: Selinexor

pomalidomide
measurable disease
elotuzumab
ixazomib
serum proteins
  • 57 views
  • 07 Jul, 2022
  • 16 locations
Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)

administration of Bortezomib in patients with B-precursor ALL with initial WBC100,000/l will improve treatment outcome? Whether the administration of Idarubicin instead Daunorubicin in low-risk T-ALL

childhood all
daunorubicin
b-cell acute lymphoblastic leukemia
lymphoid leukemia
adult t-cell leukemia/lymphoma
  • 179 views
  • 23 Jan, 2021
  • 59 locations
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

lymphoblastic leukemia (B-ALL) or B-lymphoblastic lymphoma (B-LLy), and the proteasome inhibitor bortezomib for those lacking targetable lesions. To improve overall treatment outcome of T acute

vincristine
prednisone
lymphoid leukemia
minimal residual disease
vorinostat
  • 308 views
  • 16 Sep, 2022
  • 7 locations
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

proportion of all relapses. Targeted therapy is also used in the form of the proteasome inhibitor bortezomib for patients with pB-ALL and slow response to the drugs of the induction chemotherapy with the

vincristine
adult t-cell leukemia/lymphoma
lymphoid leukemia
minimal residual disease
methotrexate
  • 897 views
  • 13 Feb, 2022
  • 93 locations
International Study for Treatment of High Risk Childhood Relapsed ALL 2010

The main goal of this study is to improve the outcome of children and adolescents with acute lymphoblastic leukemia with high risk first relapse by optimization of treatment strategies within a large international trial and the integration of new agents.

  • 34 views
  • 05 Mar, 2022
  • 10 locations
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects With Light Chain (AL) Amyloidosis (AFFIRM-AL)

A Phase 3 study to evaluate the efficacy and safety of birtamimab plus standard of care compared to placebo plus standard of care in patients with AL amyloidosis in Mayo Stage IV.

  • 5 views
  • 23 Sep, 2022
  • 97 locations
MInimal Residual Disease Adapted Strategy (MIDAS)

IFM 2020-02 will enroll patients eligible for ASCT less than 66 years. All patients will receive induction based on 6 cycles (28-day) of KRD-Isatuximab (Isa-KRD), in order to achieve deep responses and high MRD negativity rates. Patients will be classified at diagnosis according to cytogenetics (standard vs high-risk cytogenetics defined …

platelet count
neutrophil count
bone marrow procedure
measurable disease
erythropoietin
  • 0 views
  • 26 Apr, 2022
  • 51 locations